We are live on ! Find out more
Two Sigma Investments

Two Sigma Investments Portfolio holdings

AUM $124B
1-Year Est. Return 33.93%
This Fund
S&P 500
This Quarter Est. Return
-16.78%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.83%
AUM
$25.5B
AUM Growth
-$11.1B
Cap. Flow
-$5.25B
Cap. Flow %
-20.57%
Top 10 Hldgs %
6.83%
Holding
3,851
New
730
Increased
952
Reduced
1,216
Closed
943

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 15.44%
2 Technology 14.21%
3 Industrials 12.1%
4 Healthcare 9.72%
5 Financials 6.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AU icon
1326
AngloGold Ashanti
AU
$41.2B
$1.72M 0.01%
137,005
+55,690
+68% +$571K
SSD icon
1327
Simpson Manufacturing
SSD
$8.08B
$1.72M 0.01%
31,721
+2,243
+8% +$132K
RIGL icon
1328
Rigel Pharmaceuticals
RIGL
$716M
$1.71M 0.01%
74,503
+13,210
+22% +$373K
MRVL icon
1329
PUT
Marvell Technology
MRVL
$196B
$1.71M 0.01%
105,800
+93,700
+774% +$1.55M
ALEX
1330
DELISTED
Alexander & Baldwin
ALEX
$1.7M 0.01%
92,532
+70,969
+329% +$1.43M
GDXJ icon
1331
CALL
VanEck Junior Gold Miners ETF
GDXJ
$7.33B
$1.69M 0.01%
55,900
+17,100
+44% +$481K
FE icon
1332
CALL
FirstEnergy
FE
$27.9B
$1.69M 0.01%
44,900
-10,800
-19% -$409K
CSX icon
1333
CALL
CSX Corp
CSX
$94.5B
$1.68M 0.01%
81,300
+56,400
+227% +$1.3M
AZO icon
1334
PUT
AutoZone
AZO
$49.4B
$1.68M 0.01%
2,000
-1,000
-33% -$802K
DMC
1335
Del Monte Corp
DMC
$1.41B
$1.68M 0.01%
59,299
+46,087
+349% +$1.44M
ATRS
1336
DELISTED
Antares Pharma, Inc.
ATRS
$1.67M 0.01%
615,462
+352,830
+134% +$1.16M
TRVG
1337
trivago
TRVG
$375M
$1.67M 0.01%
+59,391
New +$1.77M
TLT icon
1338
iShares 20+ Year Treasury Bond ETF
TLT
$41.7B
$1.67M 0.01%
+13,747
New +$1.59M
IBKC
1339
DELISTED
IBERIABANK Corp
IBKC
$1.67M 0.01%
25,949
-10,132
-28% -$744K
CHTR icon
1340
Charter Communications
CHTR
$18.3B
$1.67M 0.01%
+5,850
New +$1.83M
EPZM
1341
DELISTED
Epizyme, Inc
EPZM
$1.67M 0.01%
270,213
+228,192
+543% +$1.74M
MCRN
1342
DELISTED
Milacron Holdings Corp.
MCRN
$1.67M 0.01%
140,030
+103,534
+284% +$1.56M
ZIXI
1343
DELISTED
Zix Corporation
ZIXI
$1.66M 0.01%
289,168
+55,755
+24% +$332K
MGNI icon
1344
Magnite
MGNI
$2.99B
$1.66M 0.01%
443,736
+88,410
+25% +$338K
CERN
1345
DELISTED
Cerner Corp
CERN
$1.66M 0.01%
31,555
-462,879
-94% -$26.8M
TWLO icon
1346
PUT
Twilio
TWLO
$29.5B
$1.64M 0.01%
18,400
-900
-5% -$73.1K
AVNT icon
1347
Avient
AVNT
$3.5B
$1.63M 0.01%
+56,896
New +$1.9M
PGNX
1348
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.62M 0.01%
+386,179
New +$1.97M
GAP
1349
PUT
The Gap Inc
GAP
$7.42B
$1.62M 0.01%
62,900
+35,300
+128% +$943K
PNNT
1350
Pennant Park Investment Corp
PNNT
$230M
$1.62M 0.01%
253,676
-164,565
-39% -$1.17M

Similar funds

Two Sigma Investments's Q4 2018 Portfolio in Review

As of Q4 2018, Two Sigma Investments held 3,851 positions worth $25.5B, down 30% from $36.7B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.

Two Sigma Investments withdrew a net $5.25B in Q4 2018, closing 943 positions and reducing 1,216 holdings. Its most notable exit was Elevance Health, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 13% a quarter earlier, followed by Technology and Industrials.

Against the trend, Two Sigma Investments opened a new position in Starbucks worth $176M.

  • Two Sigma Investments's largest Q4 2018 buy was Starbucks: 2,727,875 shares worth $176M.
  • Two Sigma Investments added most to SLB Ltd in Q4 2018, an estimated $230M increase.
  • Two Sigma Investments's biggest Q4 2018 reduction was Procter & Gamble, cutting an estimated $185M.
  • Two Sigma Investments fully exited Elevance Health in Q4 2018, selling an estimated $180M.
  • Two Sigma Investments's ten largest holdings make up 6.8% of its $25.5B portfolio in Q4 2018.
  • Two Sigma Investments opened 730 new positions and closed 943 in Q4 2018.
  • Two Sigma Investments's portfolio value fell 30% quarter-over-quarter to $25.5B.

Based on Two Sigma Investments's 13F filing for Q4 2018, filed 14 Feb 2019.